153 related articles for article (PubMed ID: 1554639)
1. Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery.
Murray TG; Jaffe GJ; McKay BS; Han DP; Burke JM; Abrams GW
Refract Corneal Surg; 1992; 8(1):44-8; discussion 48-53. PubMed ID: 1554639
[TBL] [Abstract][Full Text] [Related]
2. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
Hariprasad SM; Shah GK; Chi J; Prince RA
J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
[TBL] [Abstract][Full Text] [Related]
3. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA
Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal clearance of tissue plasminogen activator in the rabbit.
Jaffe GJ; Green GD; McKay BS; Hartz A; Williams GA
Arch Ophthalmol; 1988 Jul; 106(7):969-72. PubMed ID: 3134000
[TBL] [Abstract][Full Text] [Related]
5. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.
Ottiger M; Thiel MA; Feige U; Lichtlen P; Urech DM
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):779-86. PubMed ID: 18757511
[TBL] [Abstract][Full Text] [Related]
6. Use of tissue plasminogen activator for intraocular fibrinolysis in dogs.
Gerding PA; Essex-Sorlie D; Vasaune S; Yack R
Am J Vet Res; 1992 Jun; 53(6):894-6. PubMed ID: 1626779
[TBL] [Abstract][Full Text] [Related]
7. The collagen shield. A new vehicle for delivery of cyclosporin A to the eye.
Reidy JJ; Gebhardt BM; Kaufman HE
Cornea; 1990 Jul; 9(3):196-9. PubMed ID: 2373013
[TBL] [Abstract][Full Text] [Related]
8. Sonothrombolysis for intraocular fibrin formation in an animal model.
Yamashita T; Ohtsuka H; Arimura N; Sonoda S; Kato C; Ushimaru K; Hara N; Tachibana K; Sakamoto T
Ultrasound Med Biol; 2009 Nov; 35(11):1845-53. PubMed ID: 19699025
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of topically administered tissue plasminogen activator for intraocular fibrinolysis in dogs.
Gerding PA; Hamor RE; Ramsey DT; Vasaune S; Schaeffer DJ
Am J Vet Res; 1994 Oct; 55(10):1368-70. PubMed ID: 7998691
[TBL] [Abstract][Full Text] [Related]
10. Collagen shield heparin delivery for prevention of postoperative fibrin.
Murray TG; Stern WH; Chin DH; MacGowan-Smith EA
Arch Ophthalmol; 1990 Jan; 108(1):104-6. PubMed ID: 2297315
[TBL] [Abstract][Full Text] [Related]
11. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.
Behar-Cohen FF; El Aouni A; Gautier S; David G; Davis J; Chapon P; Parel JM
Exp Eye Res; 2002 Jan; 74(1):51-9. PubMed ID: 11878818
[TBL] [Abstract][Full Text] [Related]
12. [Vitreous hemorrhage after vitrectomy in diabetic retinopathy and tissue plasminogen activator].
Asensio Sánchez VM; Pérez Flández FJ; Carlos Bejarano J; Fernández Concellón L
Arch Soc Esp Oftalmol; 2002 Jan; 77(1):7-12. PubMed ID: 11813114
[TBL] [Abstract][Full Text] [Related]
13. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.
Sigurdsson HH; Konráethsdóttir F; Loftsson T; Stefánsson E
Acta Ophthalmol Scand; 2007 Sep; 85(6):598-602. PubMed ID: 17645424
[TBL] [Abstract][Full Text] [Related]
14. The use of collagen shields for drug delivery in cataract and intraocular lens surgery.
Tennen DG; Keates RH
Curr Opin Ophthalmol; 1995 Feb; 6(1):59-61. PubMed ID: 10150846
[TBL] [Abstract][Full Text] [Related]
15. Intraocular tissue plasminogen activator concentrations after subconjunctival delivery.
Lim JI; Maguire AM; John G; Mohler MA; Fiscella RG
Ophthalmology; 1993 Mar; 100(3):373-6. PubMed ID: 8460008
[TBL] [Abstract][Full Text] [Related]
16. Intracameral recombinant tissue plasminogen activator for the treatment of severe fibrin reaction in endophthalmitis.
Wu TT; Wang HH
Eye (Lond); 2009 Jan; 23(1):101-7. PubMed ID: 17901882
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry.
Ghate D; Brooks W; McCarey BE; Edelhauser HF
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2230-7. PubMed ID: 17460284
[TBL] [Abstract][Full Text] [Related]
18. Intracameral recombinant tissue plasminogen activator (r-tPA) for refractory toxic anterior segment syndrome.
Dotan A; Kaiserman I; Kremer I; Ehrlich R; Bahar I
Br J Ophthalmol; 2014 Feb; 98(2):252-5. PubMed ID: 24276695
[TBL] [Abstract][Full Text] [Related]
19. Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy.
Hesse L; Nebeling B; Schroeder B; Heller G; Kroll P
Exp Eye Res; 2000 Jan; 70(1):31-9. PubMed ID: 10644418
[TBL] [Abstract][Full Text] [Related]
20. Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
Erol N; Ozer A; Topbas S; Yildirim N; Yurdakul S
Ophthalmic Surg Lasers Imaging; 2003; 34(6):451-6. PubMed ID: 14620747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
